Browsing by Author Price, Karen

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2013Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trialsCoates, Alan; Colleoni, Marco; Fleming, Gini; Francis, Prudence; Gelber, Richard; Goldhirsch, Aron (Prof); Maibach, Rudolph; Pagani, Olivia; Price, Karen; Rabaglio, Manuela; Regan, Meredith; Ruepp, Barbara; Walley, B; School of Public Health: Public HealthAdjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials, The Breast, vol.22, 6, 2013,pp 1094-1100
2016Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to VCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Forbes, John F.; Gelber, Richard; Gianni, Lorenzo; Goldhirsch, Aron; Karlsson, Per; Price, Karen; Sun, Zhuoxin; Thurlimann, B.; School of Public Health: Public HealthAnnual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V, Journal of Clinical Oncology, vol.34, 9, 2016,pp 927-935
2010Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trialCoates, Alan; Bernhard, Jurg; Cardoso, Fatima; Gelber, Richard D. (Prof); Goldhirsch, A; Harvey, V; Pagani, O.; Phillips, Kelly-Anne; Price, Karen; Ribi, Karen; Stephens, Alisa; Sun, Zhuoxin; Thompson, Alastair; Thurlimann, B.; School of Public Health: Public HealthCognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial, The Breast, vol.19, 5,pp 388-395
2003Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node statusCoates, Alan; Byrne, Michael J.; Castiglione-Gertsch, Monica; Collins, John; Cortes-Funes, Hernan; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Golouh, Rastko; Grigolato, Piergioranni; Lindtner, Jurii; Litman, H; Maffini, Fausto; Martinez-Tello, Francisco J.; Masullo, Michele; Price, Karen; Simoncini, Edda; Spataro, Vito J.; Viale, Giuseppe; School of Public Health: Public HealthDecreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status, Cancer, vol.97,(7),2003,pp 1591-1600
2009Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.Coates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Collins, John; Crivellari, Diana; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Holmberg, Stig B.; Price, Karen; Thurlimann, Beat; School of Public Health: Public HealthIs chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93., Breast Cancer Research and Treatment, vol.113,(N/A),2009,pp 137-144
2008Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 TrialCoates, Alan; Castiglione-Gertsch, Monica; Chirgwin, Jacquie H; Colleoni, Marco; Crivellari, Diana; Del Mastro, Lucia; Forbes, John F.; Gelber, Richard D. (Prof); Gladieff, Laurence; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Rabaglio, Manuela; Smith, Ian (Prof); Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthLetrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial, Journal of Clinical Oncology, vol.26, 12, 2008,pp 1972-1979
2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.Coates, Alan; et al, various; Forbes, John F.; Giobbie-Hurder, Anita; Goldhirsch, Aron; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Smith, Ian (Prof); Thurlimann, Beat; School of Public Health: Public HealthLetrozole therapy alone or in sequence with tamoxifen in women with breast cancer., New England Journal of Medicine, vol.361, 8,pp 766-776
2008p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.Coates, Alan; Castiglione-Gertsch, Monica; Gianni, Lorenzo; Goldhirsch, Aron; Gusterson, Barry; Maffini, Fausto; Mastropasqua, M; Monti, F; Panzini, Ilaria; Price, Karen; Ravaioli, A; Regan, Meredith M.; Spataro, Vito J.; Viale, Giuseppe; School of Public Health: Public Healthp27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer., Annals of Oncology, vol.19, 4, 2008,pp 660-668
2010Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Gelber, Richard D. (Prof); Goldhirsch, A; Maiorano, Eugenio; Mastropasqua, Mauro G.; Price, Karen; Regan, Meredith M.; Viale, Giuseppe; School of Public Health: Public HealthPrognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy, Breast Cancer Research and Treatment, vol.121, 1,pp 211-218
2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Coates, Alan; Colleoni, Marco; Dell'Orto, Patrizia; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, A.; Gusterson,, B; Lang, Istvan; MacGrogan, G; Maiorano, Eugenio; Mastropasqua, M; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Price, Karen; Rasmussen, B; Regan, Meredith M.; Thurlimann, B.; Viale, Giuseppe; School of Public Health: Public HealthWhich patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial., Annals of Oncology, vol.22, 10, 2011,pp 2201-7